Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30191225 | 0.86 | PIN1 (0.54) | PIN1KCNQ2MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL11305795 | 0.86 | PIN1 (0.54) | PIN1KCNQ2MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL9540395 | 0.83 | PIN1 (0.54) | PIN1KCNQ2MTNR1AMTNR1BCRBN | |
| SCHEMBL11131384 | 0.81 | PIN1 (0.53) | PIN1KCNQ2MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL7874907 | 0.80 | PIN1 (0.51) | PIN1KCNQ2ALDH1A1 | |
| SCHEMBL11666042 | 0.80 | PIN1 (0.51) | PIN1KCNQ2MTNR1AMTNR1BTSHR | |
| SCHEMBL4830828 | 0.80 | PIN1 (0.62) | PIN1KCNQ2CRBNIDO1PDPK1 | |
| SCHEMBL907688 | 0.78 | PIN1 (0.60) | PIN1KCNQ2IDO1PDPK1ACP3 | |
| SCHEMBL2790690 | 0.78 | PIN1 (0.60) | PIN1KCNQ2IDO1PDPK1ACP3 | |
| SCHEMBL12431131 | 0.78 | PIN1 (0.60) | PIN1KCNQ2IDO1PDPK1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | PIN1 3338/4885KCNQ2 85/4885MTNR1A 395/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | PIN1 3338/4885KCNQ2 85/4885MTNR1A 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.